<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00216463</url>
  </required_header>
  <id_info>
    <org_study_id>301012CS3</org_study_id>
    <secondary_id>EudraCT No.: 2004-003934-32</secondary_id>
    <nct_id>NCT00216463</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of Varying Load and Dose of ISIS 301012 in People With Elevated LDL-cholesterol Levels</brief_title>
  <official_title>A Phase 2, Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Varying Loading and Maintenance Dosing Regimens of ISIS 301012 Administered to Hypercholesterolemic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kastle Therapeutics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kastle Therapeutics, LLC</source>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the safety and tolerability of varying dose and load
      regimens of ISIS 301012 in people who have elevated LDL-cholesterol levels.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent reduction in LDL-cholesterol from baseline</measure>
    <time_frame>14 days post dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent reduction in apoB-100 from baseline</measure>
    <time_frame>14 days post dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in HDL-cholesterol, triglycerides, total cholesterol, non-HDL cholesterol, VLDL and LP(a)</measure>
    <time_frame>14 days post dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in LDL/HDL and apoB-100/apo-A1 ratios</measure>
    <time_frame>14 days post dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Slow load with every other week maintenance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Slow load with every other week maintenance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No load; once weekly maintenance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No load; once weekly maintenance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No load; once weekly maintenance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 301012 or Placebo</intervention_name>
    <description>200 mg subcutaneous injection - 4 loading doses within the first 11 days followed by: 200 mg subcutaneous injection - every other week for 11 weeks</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 301012 or Placebo</intervention_name>
    <description>200 mg subcutaneous injection - 4 loading doses within the first 11 days followed by: 100 mg subcutaneous injection - every other week for 11 weeks</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 301012 or Placebo</intervention_name>
    <description>300 mg subcutaneous injection - every week for 13 weeks</description>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 301012 or Placebo</intervention_name>
    <description>400 mg subcutaneous injection - every week for 13 weeks</description>
    <arm_group_label>E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 301012 or Placebo</intervention_name>
    <description>200 mg subcutaneous injection - every week for 13 weeks</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI &gt;/= 25 to &lt;/= 32 kg/m^2

          -  fasting stable LDL-cholesterol &gt;/= 130 mg/dL (3.36 mmol/L) and triglycerides &lt; 400
             mg/dL (4.55 mmol/L)

          -  Females not of childbearing potential

        Exclusion Criteria:

          -  No endocrine, hematologic, renal, hepatic, metabolic, psychiatric, neurology,
             pulmonary or cardiovascular disease

          -  Subjects who test positive for hepatitis B, C or HIV

          -  Current diagnosis or known history of liver disease, such as acute or chronic
             hepatitis, liver cirrhosis, liver steatosis, or liver function abnormalities such as
             AST, ALT, GGT, or total bilirubin &gt;/= 1.5 x ULN at Screening

          -  A systolic blood pressure &gt;/= 160 mmHg or a diastolic blood pressure &gt;/= 95 mmHg on 2
             occasions during Screening

          -  Concomitant medications within 14 days of dosing, except hormone replacement therapy
             for post-menopausal women and acetylsalicylic acid or paracetamol dosed for fewer than
             five consecutive days

          -  Subject has taken any lipid-lowering drug within 30 days or five half-lives (of the
             lipid-lowering drug) whichever is longer, prior to Screening

          -  Alcohol or drug abuse within 2 years of Screening

          -  Donated blood (450 mL) within the 3 months prior to Screening or suffered significant
             blood loss equal to a blood donor portion

          -  Subject smokes &gt; 10 cigarettes, or more than one pipe or one cigar per day
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Genzyme, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>D-14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2005</study_first_submitted>
  <study_first_submitted_qc>September 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>August 1, 2016</last_update_submitted>
  <last_update_submitted_qc>August 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2016</last_update_posted>
  <responsible_party>
    <name_title>Medical Monitor</name_title>
    <organization>Genzyme Coporation</organization>
  </responsible_party>
  <keyword>LDL-cholesterol</keyword>
  <keyword>apoB-100</keyword>
  <keyword>apoB-48</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mipomersen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

